Laurus Labs, a leading integrated pharmaceutical company in India with presence across the globe and partner, Aspen Pharmacare, South Africa's leading pharmaceutical company, have launched a new HIV drug with the triple combination of Tenofovir Disoproxil Fumarate, Lamivudine and Dolutegravir (TLD) in South Africa on 26 November 2018.
Earlier, Aspen Pharma received approvals for the dossier where Aspen Port Elizabeth and Laurus Labs Visakhapatnam are registered as manufacturing facilities, from the South African Health Products Regulatory Authority (SAHPRA). Named Emdolten™, the product provides significant benefits to existing therapies, including countering drug resistance that often develops with older HIV treatments. This once-a-day triple combination tablet is positioned to become a preferred first-line ARV choice in multiple markets. It will be available in 50mg/300mg/300mg dosages.
As part of the partnership, Aspen launched the product in South Africa for the private market and Laurus Labs will supply the API, from its manufacturing facility located in Jawaharlal Nehru Pharma city, Visakhapatnam, India. This state-of-the-art facility is approved by USFDA.
Dr. Satyanarayana Chava, Founder and CEO, Laurus Labs said, "we convey our best wishes to our partner Aspen Pharma on the new product launch and we are happy to contribute to the treatment of millions of HIV patients across the globe through our fully integrated and the state of the art manufacturing facilities. I am sure that the new triple combination drug will contribute to the successful treatment of patients affected by HIV and AIDS."
Stavros Nicolaou, Senior Executive for Aspen Pharmacare stated "The Aspen Pharmacare and Laurus Labs intervention is one with an outstanding track record that has delivered millions of patient treatment packs to HIV infected patients on the African continent, Laurus Labs supplying the API and Aspen the ARV formulation. Through Emdolten™, which provides the latest ARV triple cocktail, cutting edge technology, many hundreds and thousands of patients will continue to benefit from the Aspen/Laurus intervention."
Shares of Laurus Labs Ltd was last trading in BSE at Rs.383 as compared to the previous close of Rs. 375.75. The total number of shares traded during the day was 2589 in over 103 trades.
The stock hit an intraday high of Rs. 386 and intraday low of 378. The net turnover during the day was Rs. 992502.